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Abbreviations {#nc005}
=============

ACS

:   Acute Coronary Syndrome

AHF

:   Acute Heart Failure

BMI

:   Body Mass Index

DBP

:   Diastolic Blood Pressure

DLD

:   Dyslipidemia

DM

:   Diabetes Mellitus

EF

:   Ejection Fraction

eGFR

:   Estimated Glomerular Filtration Rate

HEARTS

:   Heart Function Assessment Registry Trial In Saudi Arabia

HG

:   Hyperglycemia

HR

:   Heart Rate

HTN

:   Hypertension

IHD

:   Ischemic Heart Disease

IQR

:   Interquartile Range

RBS

:   Random Blood Sugar

SBP

:   Systolic Blood Pressure

SD

:   Standard Deviation

1. Introduction {#s0005}
===============

Acute heart failure (AHF) continues to be a burdensome problem to healthcare systems and is a leading cause of frequent hospitalizations and long-term medical care [@b0005]. Multiple illnesses coexist with HF and influence its prognosis [@b0010], [@b0015], [@b0020]. Diabetes mellitus (DM) is known as one of the most commonly associated comorbidities in HF patients with a prevalence ranging from 25% to 40% [@b0025], [@b0030]. Data from major HF registries indicate that DM worsens hospital outcomes and increases short-term mortality rates [@b0030], [@b0035], [@b0040], [@b0045], [@b0050], [@b0055]. Although the impact of DM on HF outcomes is known, the role of hyperglycemia (HG), whether new-onset or in the context of a preexisting DM, remains controversial [@b0060], [@b0065], [@b0070], [@b0075], [@b0080], [@b0085], [@b0090], [@b0095], [@b0100]. Several reports have suggested a negative impact of HG on AHF mainly affecting hospital outcomes and overall survival [@b0060], [@b0065], [@b0070], [@b0075], [@b0080], [@b0085], [@b0090], yet others have not shown similar findings [@b0095], [@b0100].

HG in acute coronary syndromes (ACS) has been widely investigated. The Diabetes Mellitus Insulin-Glucose Infusion in Acute Myocardial Infarction (DIGAMI) trial showed a survival benefit in ACS patients with tight glycemic control [@b0105]. This was later confirmed in other major trials [@b0110], [@b0115], [@b0120]. Currently, the 2013 American Heart Association/American College of Cardiology guidelines recommend targeting sugar levels \<180 mg/dL [@b0125]. Glycemic control has become an integral part of the standard management of ACS, however the impact of extrapolating this evidence across the spectrum of all cardiovascular diseases is yet to be determined.

We sought to determine the relationship between HG and hospital adverse outcomes, as well as short- and long-term mortality rates in AHF patients using data from the Heart Function Assessment Registry Trial in Saudi Arabia (HEARTS).

2. Materials and methods {#s0010}
========================

HEARTS protocol has been described previously [@b0130], [@b0135]. Briefly, HEARTS is a prospective registry that enrolled 2609 consecutive patients with a primary admission diagnosis of AHF. Eighteen tertiary care centers in different regions of Saudi Arabia participated in this registry. Enrollment took place between October 2009 and December 2010, with clinical follow-up until January 2013. The definition of HF was according to the European Society of Cardiology guidelines for the diagnosis and treatment of acute and chronic HF [@b0140]. The study was approved by the institutional review board at each participating hospital and complied with the Declaration of Helsinki.

Patients were eligible for this analysis if baseline random blood sugar (RBS) values were available. The diagnosis of DM was based on medical records documentation, patient self-reporting, or if the patient was taking diabetic medications. Patients were labeled as having HG if their RBS was ≥11.1 mmol/L, according to the American Diabetes Association guidelines [@b0145]. We described patients' baseline characteristics, therapies, hospital course, and hospital mortality rates. Additionally, we obtained the vital status after 30 days, 1 year, 2 years, and 3 years following hospital discharge by a telephone interview and verified these data as needed using hospital records.

2.1. Statistical analysis {#s0015}
-------------------------

Categorical data were summarized with absolute numbers and percentages. Numeric data were summarized with mean and standard deviation (SD) or median and interquartile range (IQR). Comparisons between different groups were performed using Chi-square test or Fisher's exact for categorical variables and independent sample *t* test or Mann--Whitney *U* test for continuous variables. Kaplan--Meier analysis was applied to plot the cumulative survival and differences between curves were assessed using the log-rank test. We used logistic regression models to estimate unadjusted and adjusted odds ratios (OR) for mortality rates. We adjusted for age, sex, estimated glomerular filtration rate (eGFR), ACS, body mass index (BMI), systolic blood pressure (SBP), diastolic blood pressure (DBP), heart rate (HR), AHF type, ejection fraction (EF), dyslipidemia (DLD), anemia, hypertension (HTN), and DM. Logistic regression with interaction terms was used to test the statistical significance of the interaction between HG and other baseline factors. To estimate the strength of association in subgroups we used OR with 95% confidence intervals (CI). A two-sided *p* value \<0.05 was considered statistically significant. All analyses were performed using SAS/STAT software, version 9.2 (SAS Institute Inc., Cary, NC, USA.) and R software (R Foundation for Statistical Computing, Vienna, Austria).

3. Results {#s0020}
==========

Of the 2609 patients enrolled in HEARTS, 2511 (96.2%) patients were eligible for the present analysis. A total of 1783 (71%) were in the non-HG group, while 728 (29%) had HG at baseline. HG patients were generally older and had higher BMIs. Further, they were more likely to be diabetic, hypertensive, and dyslipidemic (*p* \< 0.001 for all comparisons; [Table 1](#t0005){ref-type="table"}).Table 1Baseline characteristics.Overall\
2511Non-HG\
1783 (71%)HG\
728 (29%)*pDemographics*Age61.34 ± 1560.65 ± 15.663.38 ± 12.4\<0.001Saudi2135 (85)1521 (85.3)614 (84.3)0.539Male1653 (65.8)1207 (67.7)446 (61.3)0.002Body mass index29.2 ± 6.729 ± 6.729.7 ± 6.70.028  *Risk factors*Diabetes mellitus1629 (65.1)955 (53.8)674 (92.7)\<0.001Smoker/ex-smoker844 (33.6)614 (34.4)230 (31.6)0.171Hypertension1781 (71.4)1195 (67.4)586 (81.3)\<0.001Dyslipidemia870 (36.8)550 (32.5)320 (47.8)\<0.001  *History of cardiovascular diseases*Heart failure1607 (64.2)1179 (66.3)428 (59)\<0.001Ischemic heart disease1342 (54)908 (51.6)434 (59.9)\<0.001TIA/stroke241 (9.6)156 (8.8)85 (11.7)0.025PAD97 (3.9)60 (3.4)37 (5.1)0.044PCI326 (13)222 (12.5)104 (14.3)0.219CABG257 (10.3)175 (9.8)82 (11.3)0.282RHD172 (6.9)137 (7.7)35 (4.8)0.010Other VHD359 (14.4)271 (15.3)88 (12.2)0.045Atrial fibrillation390 (15.6)313 (17.6)77 (10.6)\<0.001VT/VF60 (2.4)50 (2.8)10 (1.4)0.033ICD216 (8.6)179 (10.1)37 (5.1)\<0.001CRT81 (3.2)67 (3.8)14 (1.9)0.018  *History of other chronic medical illnesses*Anemia1116 (44.6)781 (44)335 (46.2)0.308CKD on dialysis70 (9.5)45 (8.7)25 (11.4)0.256CKD not on dialysis668 (90.5)473 (91.3)195 (88.6)Chronic lung disease179 (7.1)131 (7.4)48 (6.6)0.505[^1][^2]

Compared with patients with HG, non-HG patients were more likely to have a history of HF, valvular heart diseases (rheumatic and nonrheumatic), arrhythmias (both atrial and ventricular), and to have undergone cardiac device implantation. However, vascular comorbidities such as ischemic heart disease (IHD), strokes/transient ischemic attacks, and peripheral arterial disease were significantly higher among patients with HG ([Table 1](#t0005){ref-type="table"}).

[Table 2](#t0010){ref-type="table"} demonstrates the types, etiologies, and exacerbating factors of AHF. HG patients were more likely to present with acute *de novo* HF while non-HG patients were more likely to present with acute on chronic HF (*p* \< 0.001 for group comparison). IHD was the prime etiology for AHF in patients with HG, while nonischemic etiologies of AHF were seen more often in non-HG patients (*p* \< 0.001 for group comparison). ACS and uncontrolled HTN were the main reasons for AHF exacerbation among HG patients, and had occurred more frequently compared to the non-HG group.Table 2Heart failure types, etiologies, and exacerbating factors for acute heart failure.Overall\
2511Non-HG\
1783 (71%)HG\
728 (29%)*pAcute heart failure type*Acute *de novo* HF904 (36)604 (33.9)300 (41.2)\<0.001Acute on Chronic HF1607 (64)1179 (66.1)428 (58.8)  *Etiology*Ischemic1419 (56.5)937 (52.5)482 (66.2)\<0.001Nonischemic1092 (43.5)846 (47.4)246 (33.8)  *HF exacerbation factors*NSTACS702 (28)440 (24.7)262 (36)\<0.001STEMI266 (10.6)164 (9.2)102 (14)\<0.001Uncontrolled hypertension506 (20.1)332 (18.6)174 (23.9)0.003Noncompliance to HF medications523 (20.8)403 (22.6)120 (16.5)\<0.001Noncompliance to diet628 (25)493 (27.6)135 (18.5)\<0.001Worsening renal failure443 (17.6)341 (19.1)102 (14)0.002Arrhythmia275 (10.9)210 (11.8)65 (8.9)0.038Infections524 (20.9)363 (20.4)161 (22.1)0.326COPD exacerbation94 (3.7)74 (4.1)20 (2.7)0.093[^3][^4]

Patients with HG had a higher mean baseline SBP (134.5 vs. 126.6, *p* \< 0.001), higher rates of positive troponin levels (51.3% vs. 32.6%, *p* \< 0.001), and a higher proportion of low eGFR defined as \<60 mL/min/1.73 m^2^ (60.2% vs. 51.0%, *p* \< 0.001). Non-HG patients were more likely to have severe left ventricular systolic dysfunction (50.6% vs. 39.7%; *p* \< 0.001). Among the patients who underwent coronary angiogram during the same admission (*n* = 720), significant left main, three-vessel, and double-vessel disease were more frequently seen in patients with HG. Further comparisons in clinical presentations and baseline investigations are depicted in [Table 3](#t0015){ref-type="table"}.Table 3Clinical presentation and investigations.Overall\
2511Non-HG\
1783 (71%)HG\
728 (29%)*pHemodynamic parameters*Systolic blood pressure128.7 ± 31.3126.6 ± 30.8134.5 ± 32.5\<0.001Diastolic blood pressure74.1 ± 17.973.8 ± 18.275.5 ± 17.60.030Heart rate88.8 ± 2187.9 ± 20.991.4 ± 21.3\<0.001  *Lab results*RBS (mmol/L), median (IQR)8 (6)7 (3)15 (6)\<0.001Sodium (mmol/L)135.1 ± 5.3135.5 ± 5.2134.2 ± 5.6\<0.001BUN (μmol/L)11.9 ± 9.111.7 ± 9.212.2 ± 8.80.288Hemoglobin (g/dL)12.4 ± 2.212.5 ± 2.2112.4 ± 2.30.521Creatinine (µmol/L)109 (70)108 (69)118 (58)0.197Pro BNP (pmol/L), median (IQR)675 (668)705 (650)664 (1095)0.632Troponin positive848 (38)516 (32.6)332 (51.3)\<0.001eGFR \< 601346 (53.7)909 (51)437 (60.2)\<0.001  *Electrocardiography*Wide QRS duration361 (14.4)272 (15.3)89 (12.3)0.049Left bundle branch block288 (11.5)197 (11.1)91 (12.5)0.300  *LV systolic function by echocardiography*Normal (EF \> 55%)332 (13.8)224 (13.1)108 (15.6)\<0.001Mild (EF = 40--55%)321 (13.3)202 (11.8)119 (17.2)Moderate (EF = 30--39.9%)611 (25.4)420 (24.5)191 (27.6)Severe (EF \< 30%)1141 (47.4)866 (50.6)275 (39.7)  *Coronary angiography (n = 720)*LMD/TVD255 (34.7)166 (31.2)89 (44.1%)0.001Significant double VD113 (15.4)70 (13.2)43 (21.3)0.006Significant single VD97 (13.2)74 (13.9)23 (11.4)0.367Nonsignificant CAD79 (10.8)60 (11.3)19 (9.4)0.465Normal176 (24)153 (28.8)23 (11.4)\<0.001[^5][^6]

Hospital therapies and discharge medications are shown in [Fig. 1](#f0005){ref-type="fig"}. β-blockers and aldosterone antagonists use was higher in non-HG patients, both prior to hospital admission, and upon discharge, while aspirin and statin therapy were prescribed more frequently in HG patients upon discharge.Figure 1Differences in evidence-based medical therapies used before admission (A) and at discharge (B). ^\*^*p* \< 0.05. AA = aldosterone antagonists; ACEI = angiotensin converting enzyme inhibitors; ARB = angiotensin receptors blockers; BB = β-blockers.

Hospital procedures, complications, as well as hospital, short-, and long-term mortality rates are shown in [Table 4](#t0020){ref-type="table"}. Compared to HG patients, the non-HG group were more likely to receive device therapies (implantable cardioverter defibrillators and cardiac resynchronization therapy) and were less likely to require mechanical ventilation. Apart from a higher rate of hospital recurrence of AHF in patients with non-HG (33.1% vs. 28.2%; *p* = 0.015), there were no differences in the rate of hospital complications between the two groups.Table 4Adverse hospital outcomes, 30-day, 1-, 2-, and 3-year mortality rates.Overall\
2511Non-HG\
1783 (71%)HG\
728 (29%)*pHospital procedures*Dialysis119 (4.7)79 (4.4)40 (5.5)0.255Ventilation282 (11.2)186 (10.4)96 (13.2)0.047Intraaortic balloon pumps84 (3.35)54 (3)30 (4.1)0.167Pacing35 (1.4)20 (1.1)15 (2.1)0.069Hospital ICD145 (5.8)127 (7.1)18 (2.5)\<0.001Hospital CRT65 (2.6)56 (3.1)9 (1.2)0.006  *Hospital complications*Recurrent CHF796 (31.7)591 (33.1)205 (28.2)0.015Sepsis186 (7.4)124 (6.9)62 (8.5)0.175Shock218 (8.7)147 (8.2)71 (9.7)0.223Cardiogenic162 (74.3)113 (76.9)49 (69)0.271Noncardiogenic21 (9.6)11 (7.5)10 (14.1)Both35 (16.1)23 (15.6)12 (16.9)AF requiring therapy150 (6)113 (6.3)37 (5.1)0.229VT/VF106 (4.2)67 (3.8)39 (5.4)0.071Major bleeding35 (1.4)26 (1.5)9 (1.2)0.667TIA/stroke45 (1.8)29 (1.6)16 (2.2)0.328  *All-cause mortality*In-hospital mortality163 (6.5)99 (5.5)64 (8.8)0.00330-d mortality204 (8.1)128 (7.2)76 (10.4)0.0071 y mortality487 (19.4)328 (18.4)159 (21.8)0.0492 y mortality589 (23.5)406 (22.8)183 (25.1)0.2093 y mortality607 (24.2)416 (23.4)191 (26.2)0.127[^7][^8]

The observed hospital, 30-day, and 1-year mortality rates were significantly higher in patients with HG (8.8% vs. 5.5%; *p* = 0.003, 10.4% vs. 7.2%; *p* = 0.007, and 21.8 vs. 18.4; *p* = 0.049, respectively). There were no differences in the 2- and 3-year mortality rates between the two groups. After adjusting for important confounders, HG remained an independent predictor for hospital and 30-day mortality (OR = 1.61; 95% CI 1.07--2.42, *p* = 0.022, and OR = 1.55; 95% CI 1.07--2.25, *p* = 0.021, respectively), [Table 5](#t0025){ref-type="table"}. A Kaplan--Meier plot comparing survival rates between the groups showed that patients with HG had significantly lower survival rates compared with patients with non-HG (log-rank test *p* = 0.038), [Fig. 2](#f0010){ref-type="fig"}.Figure 2Survival analysis using Kaplan--Meier plots in hyperglycemics versus nonhyperglycemics.Table 5Crude and adjusted odds ratios and 95% confidence intervals for short- and long-term mortality in acute heart failure.All-cause mortalityCrude OR (95% CI)*p*Adjusted OR (95% CI)*p*Hospital mortality1.64 (1.18--2.27)0.0031.61 (1.07--2.42)0.02230-d mortality1.50 (1.11--2.02)0.0081.55 (1.07--2.25)0.0211 y mortality1.24 (1.00--1.53)0.0491.25 (0.96--1.63)0.1002 y mortality1.14 (0.93--1.39)0.2091.13 (0.88--1.45)0.3543 y mortality1.17 (0.96--1.42)0.1271.17 (0.91--1.50)0.209[^9]

The interaction between HG and mortality was assessed in several patient subgroups. Subgroups assessed included patients stratified by age (≥70 years vs. \<70 years), sex (males vs. females), prior diagnosis of DM, use of insulin, HF etiology (ischemic vs. nonischemic), type of AHF (*de novo* vs. acute on chronic), eGFR (≥60 mL/min/1.73 m^2^ vs. \<60 mL/min/1.73 m^2^), EF (≥40% vs. \<40%), SBP (≥90 mmHg vs. \<90 mmHg), and history of anemia. A significant interaction between HG and EF was observed, where the negative impact of HG on 30-day mortality was worse in patients with an EF \< 40% (EF \< 40%, OR = 1.69; 95% CI 1.18--2.42, *p* = 0.003, vs. EF ≥ 40%, OR = 0.72; 95% CI 0.37--1.39, *p* = 0.331, *p* value for interaction = 0.025). This interaction between HG and EF was not seen in hospital or 1-year mortality. Additionally, a strong interaction was observed between HG and anemia. Anemic patients with HG had a higher hospital mortality compared with nonanemic patients (anemia present, OR = 2.69; 95% CI 1.62--4.46, *p* \< 0.001 vs. anemia absent, OR = 1.10; 95% CI 0.71--1.73, *p* = 0.66, *p* for interaction = 0.01). This interaction between anemia and HG also impacted short- and long-term mortality (data not shown).

4. Discussion {#s0025}
=============

To our knowledge, this is the first report from the Arab Middle East examining the impact of glycemic status on the outcomes of patients with AHF. We found that almost 30% of our patients had HG upon hospital admission. Irrespective of their diabetic status and other comorbidities, these patients had a worse prognosis.

Data on the impact of HG on AHF outcomes are inconsistent [@b0060], [@b0065], [@b0070], [@b0075], [@b0080], [@b0085], [@b0090], [@b0095], [@b0100]. Some reports have suggested that HG is independently associated with hospital [@b0060], [@b0065], [@b0070], [@b0075], [@b0080], 30- [@b0085], [@b0090], and 60-day [@b0070] mortality. However, this association with mortality was less robust in the long term [@b0060], [@b0065], [@b0095], [@b0100]. Conversely, other reports did not show an association between HG and short-term mortality [@b0095], [@b0100] but rather an association with long-term mortality [@b0090]. Our data agree with the general pattern of these reports where HG is more likely to be related to short-term mortality. The discrepancy in the findings of these studies could be explained by the diverse methods and inclusion and exclusion criteria that were used, such as the exclusion of diabetic patients [@b0070], [@b0080], [@b0095], using different blood sugar measurements (random and/or fasting) and cutoffs, or selecting patients under special circumstances such as AHF patients admitted to the intensive care only [@b0075], [@b0095].

Our subgroup analysis suggests an interaction between HG and an anemic status as well as with EF. The test of interaction is hypothesis generating and may suggest colinearity between HG and anemia on one hand, and HG and an EF \< 40% on the other hand. Alternatively, anemia and a low EF such as HG simply reflect disease severity. Therefore, a risk score for AHF that combine all potential risk factors for worse prognosis is essential for targeted therapy and hospital disposition. In addition, the high readmission and mortality rates in AHF patients further necessitate conducting trials focusing on risk score designing and validation [@b0150]. Indeed, there have been many proposed risk scores that correlate with hospital and postdischarge mortality [@b0155], [@b0160], [@b0165]. However, none of them is implemented as a standard-of-care in current clinical practice.

Whether HG in AHF serves as a marker of disease severity or a direct cause for adverse outcomes remains unclear. Some have suggested that chronic elevation of blood sugar as evident by an elevated HbA1c could cause direct injury to the myocardium [@b0170]. In addition, persistent hyperglycemia (e.g., Type I DM) may lead to an insulin-resistant state [@b0175] and impaired glucose uptake by the myocardium shifting the energy generation pathway towards utilization and oxidization of free fatty acids by the myocardium [@b0180], [@b0185] which in turn may promote arrhythmogenesis [@b0190]. Finally, HG may impair the cardiac function through various mechanisms such as oxidative stress [@b0195], [@b0200], endothelial atherogenesis, and vascular inflammation [@b0205]. However, HG in AHF can simply be stress-induced. The normal physiological response to stress insults leads to high glucose levels as a result of sympathetic nervous system activation and/or excessive release of stress hormones such as cortisol [@b0210], [@b0215]. The fact that HG seemed to be an independent predictor of short- rather than long-term mortality might support the premise that HG is merely a marker of severity rather than a direct cause of mortality.

The clinical implications of our findings are numerous. Firstly, the measurement of RBS in the Emergency Department is simple and provides very useful information in predicting the hospital course and prognosis of AHF. Therefore, it can potentially be used as a tool amongst other tools for risk stratification in AHF patients. Secondly, HG in the context of AHF was found to be predictive of the development of new-onset DM [@b0090]. Similar findings were observed in critically ill patients [@b0220], and patients with ACS [@b0225]. This should encourage treating physicians to screen patients with abnormal glucose levels for DM following the acute phase of HF. Finally, as HG is an independent predictor of short-term adverse outcomes in the context of AHF, this should raise interest in studies examining the efficacy of aggressive glycemic control on the outcomes of AHF patients. Despite the general recommendation by the American Diabetes Association to aim for strict glycemic control in any hospital admission regardless of the primary diagnosis [@b0230], the evidence for this practice in AHF is weak.

This study suffered from several limitations. Data on hospital readmission rates were not collected in the HEARTS registry, therefore, the impact of HG on AHF readmissions rates and postdischarge disease deterioration could not be assessed. In addition, the registry only recorded all-cause mortality, and thus we are unable to comment on the rates of cardiovascular mortality. Finally, HbA1c data were not collected systematically. Hence, we could not determine if HG is a new event or simply a reflection of an undiagnosed DM.

5. Conclusion {#s0030}
=============

Our study highlights the deleterious short-term prognostic impact of HG in AHF patients. Our findings should prompt the design of clinical trials addressing the impact of tight glycemic control in AHF on clinical outcomes.
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[^1]: Data are presented as *n* (%) or mean ± SD.

[^2]: CABG = coronary artery bypass grafting; CKD = chronic kidney disease; CRT = cardiac resynchronization therapy; HG = hyperglycemia; ICD = implantable cardioverter defibrillator; PAD = peripheral arterial disease; PCI = percutaneous coronary intervention; RHD = rheumatic heart disease; SD = standard deviation; TIA = transient ischemic attack; VF = ventricular fibrillation; VHD = valvular heart disease; VT = ventricular tachycardia.

[^3]: Data are presented as *n* (%).

[^4]: COPD = chronic obstructive pulmonary disease; HF = heart failure; HG = hyperglycemia, NSTACS = non-ST elevation myocardial infarction; STEMI = ST-elevation myocardial infarction.

[^5]: Data are presented as *n* (%) or mean ± SD, unless otherwise indicated.

[^6]: BNP = brain natriuretic peptide; BUN = blood urea nitrogen; CAD = coronary artery disease; EF = ejection fraction; eGFR = estimated glomerular filtration rate; HG = hyperglycemia; IQR = interquartile range; LMD = left main disease; RBS = random blood sugar; SD = standard deviation; TVD = three vessel disease; VD = vessel disease.

[^7]: Data are presented as *n* (%).

[^8]: AF = atrial fibrillation; CHF = congestive heart failure; CRT = cardiac resynchronization therapy; HG = hyperglycemia; ICD = implantable cardioverter defibrillator; TIA = transient ischemic attack; VF = ventricular fibrillation. VT = ventricular tachycardia.

[^9]: CI = confidence interval; OR = odds ratio.
